Notice of Amendment, 78974-78976 [2022-28013]
Download as PDF
78974
Federal Register / Vol. 87, No. 246 / Friday, December 23, 2022 / Notices
Annual
number of
respondents
Information collection title
Placement Authorization (Form P–1) ..............................................................
Authorization for Medical, Dental, and Mental Health Care (Form P–2) ........
Notice of Placement in a Restrictive Setting (Form P–4/4s) ...........................
Community-Based Care Placement Memo (Form P–5) ..................................
UC Referral (Form P–7) ..................................................................................
Care Provider Checklist for Transfers to Influx Care Facilities (Form P–8) ...
Medical Checklist for Transfers (Form P–9A) .................................................
Medical Checklist for Influx Transfers (Form P–9B) .......................................
Transfer Request (Form P–10A) .....................................................................
Transfer Request (Form P–10A) .....................................................................
Influx Transfer Request (Form P–10B) ...........................................................
Transfer Summary and Tracking (Form P–11) ...............................................
Program Entity (Form P–12) ............................................................................
UC Profile (Form P–13) ...................................................................................
ORR Transfer Notification—ORR Notification to Immigration and Customs
Enforcement Chief Counsel of Transfer of UC and Request to Change
Address/Venue (Form P–14) .......................................................................
Family Group Entity (Form P–15) ....................................................................
Influx Transfer Manifest (Form P–16) ..............................................................
Influx Transfer Manual and Prescreen Criteria Review (Form P–17) .............
Notice of Administrative Review (Form P–18) ................................................
Estimated Annual Burden Hours
Total: 7,649,415.
Comments: The Department
specifically requests comments on (a)
whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) the quality, utility,
and clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Consideration will be given
to comments and suggestions submitted
within 60 days of this publication.
Authority: 6 U.S.C. 279; 8 U.S.C.
1232; Flores v. Reno Settlement
Agreement, No. CV85–4544–RJK (C.D.
Cal. 1996).
Mary B. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2022–27908 Filed 12–22–22; 8:45 am]
BILLING CODE 4184–45–P
TKELLEY on DSK125TN23PROD with NOTICE
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Notice of Amendment
ACTION:
Notice of amendment.
The Secretary is amending the
Declaration issued in the Federal
Register of April 11, 2017, pursuant to
SUMMARY:
VerDate Sep<11>2014
20:36 Dec 22, 2022
Jkt 259001
Frm 00062
Fmt 4703
Sfmt 4703
Average
burden hours
per response
Annual total
burden hours
262
262
15
110
25
262
262
262
262
275
262
262
262
262
536
536
114
337
4,909
19
49
96
67
67
96
67
12
468
0.08
0.08
0.33
0.25
1.00
0.25
0.08
0.17
0.42
0.33
0.42
0.17
0.50
0.75
11,235
11,235
564
9,268
122,725
1,245
1,027
4,276
7,373
6,080
10,564
2,984
1,572
91,962
262
25
3
262
200
67
120
12
56,213
1
0.17
0.08
0.33
0.50
0.83
2,984
240
12
7,363,903
166
section 319F–3 of the Public Health
Service Act to extend the effective time
period of the Declaration.
DATES: This amendment of the April 11,
2017 Declaration is effective January 1,
2023.
FOR FURTHER INFORMATION CONTACT: L.
Paige Ezernack, Administration for
Strategic Preparedness and Response,
Department of Health and Human
Services, 200 Independence Avenue
SW, Washington, DC 20201; 202–260–
0365, paige.ezernack@hhs.gov.
SUPPLEMENTARY INFORMATION: The
Public Readiness and Emergency
Preparedness Act (PREP Act) authorizes
the Secretary of Health and Human
Services (the Secretary) to issue a
Declaration to provide liability
immunity to certain individuals and
entities (Covered Persons) against any
claim of loss caused by, arising out of,
relating to, or resulting from the
administration or use of medical
countermeasures (Covered
Countermeasures), except for claims
that meet the PREP Act’s definition of
willful misconduct. The Secretary may,
through publication in the Federal
Register, amend any portion of a
Declaration.
The PREP Act was enacted on
December 30, 2005, as Public Law 109–
148, Division C, Section 2. It amended
the Public Health Service (PHS) Act,
adding Section 319F–3, which
addresses liability immunity, and
Section 319F–4, which creates a
compensation program. These sections
are codified in the U.S. Code as 42
U.S.C. 247d–6d and 42 U.S.C. 247d–6e,
respectively. Section 319F–3 of the PHS
PO 00000
Annual
number of
responses per
respondent
Act has been amended by the Pandemic
and All-Hazards Preparedness
Reauthorization Act (PAHPRA), Public
Law 113–5, enacted on March 13, 2013,
and the Coronavirus Aid, Relief, and
Economic Security (CARES) Act, Public
Law 116–136, enacted on March 27,
2020, to expand Covered
Countermeasures under the PREP Act.
This Secretary is now amending the
Declaration to extend the time period
for which liability immunity is in effect
for all of the Covered Countermeasures
to December 31, 2027.
Renewal of PREP Act declaration for
nerve agent and insecticide threats is
requested due to the continued national
security threat posed by these chemical
threats. Nerve agent and insecticide
threats have the potential to cause
significant morbidity and mortality in
the event of large-scale exposures. PREP
Act coverage of countermeasures is
critical to the engagement with potential
product sponsors due to the limited
commercial market of products in this
threat space. Covered countermeasures
for nerve agents and insecticides will
continue to be a part of the
preparedness posture for the United
States, both in terms of stockpiling
current products and development nextgeneration candidates. Extension of the
PREP Act declaration for
countermeasures against nerve agents
and insecticides is essential.
Unless otherwise noted, all statutory
citations below are to the U.S. Code.
E:\FR\FM\23DEN1.SGM
23DEN1
Federal Register / Vol. 87, No. 246 / Friday, December 23, 2022 / Notices
Republished Declaration
Declaration, as Amended, for Public
Readiness and Emergency Preparedness
Act Coverage for Nerve Agents and
Certain Insecticides (Organophosphorus
and/or Carbamate) Countermeasures
This Declaration amends the April 11,
2017, Declaration under the Public
Readiness and Emergency Preparedness
Act. To the extent any term of the prior
Declaration is inconsistent with any
provision of this Republished
Declaration, the terms of this
Republished Declaration are controlling.
I. Determination of Public Health
Emergency or Credible Risk of Future
Public Health Emergency
42 U.S.C. 247d–6d(b)(1)
I have determined that there is a
credible risk that the release of nerve
agents or organophosphorus insecticides
and the resulting organophosphorus
poisoning or release of carbamate
insecticides and the resulting carbamate
poisoning may, in the future, constitute
a public health emergency.
II. Factors Considered
42 U.S.C. 247d–6d(b)(6)
I have considered the desirability of
encouraging the design, development,
clinical testing, or investigation,
manufacture, labeling, distribution,
formulation, packaging, marketing,
promotion, sale, purchase, donation,
dispensing, prescribing, administration,
licensing, and use of the Covered
Countermeasures.
III. Recommended Activities
42 U.S.C. 247d–6d(b)(1)
I recommend, under the conditions
stated in this Declaration, the
manufacture, testing, development,
distribution, administration, or use of
the Covered Countermeasures.
IV. Liability Immunity
42 U.S.C. 247d–6d(a), 247d–6d(b)(1)
Liability immunity as prescribed in
the Public Readiness and Emergency
Preparedness (PREP) Act and conditions
stated in this Declaration is in effect for
the Recommended Activities described
in Section III.
TKELLEY on DSK125TN23PROD with NOTICE
V. Covered Persons
42 U.S.C. 247d–6d(i)(2), (3), (4), (6),
(8)(A) and (B)
Covered Persons who are afforded
liability immunity under this
Declaration are manufacturers,
distributors, program planners,
‘‘qualified persons,’’ and their officials,
agents, and employees, as those terms
VerDate Sep<11>2014
20:36 Dec 22, 2022
Jkt 259001
are defined in the PREP Act, and the
United States.
In addition, I have determined that
the following additional persons are
qualified persons: (a) Any person
authorized in accordance with the
public health and medical emergency
response of the Authority Having
Jurisdiction, as described in section VII
below, to prescribe, administer, deliver,
distribute or dispense the Covered
Countermeasures, and their officials,
agents, employees, contractors and
volunteers, following a declaration of an
emergency; (b) Any person authorized
to prescribe, administer, or dispense the
Covered Countermeasures or who is
otherwise authorized to perform an
activity under an Emergency Use
Authorization in accordance with
section 564 of the Federal Food, Drug,
and Cosmetic (FD&C) Act, and; (c) Any
person authorized to prescribe,
administer, or dispense Covered
Countermeasures in accordance with
Section 564A of the FD&C Act.
VI. Covered Countermeasures
42 U.S.C. 247d–6b(c)(1)(B), 42 U.S.C.
247d–6d(i)(1) and (7)
Covered Countermeasures are any
antidote; any other drug; all components
and constituent materials of these
antidotes and other drugs; all devices
and their constituent components used
in the administration of these antidotes
and other drugs; any diagnostic; or any
other device to identify, prevent, or treat
organophosphorus or carbamate
poisoning or adverse events from such
countermeasures.
Covered Countermeasures must be
‘‘qualified pandemic or epidemic
products,’’ or ‘‘security
countermeasures,’’ or drugs, biological
products, or devices authorized for
investigational or emergency use, as
those terms are defined in the PREP Act,
the FD&C Act, and the Public Health
Service Act.
VII. Limitations on Distribution
42 U.S.C. 247d–6d(a)(5) and (b)(2)(E)
I have determined that liability
immunity is afforded to Covered
Persons only for Recommended
Activities involving Covered
Countermeasures that are related to:
(a) Present or future Federal contracts,
cooperative agreements, grants, other
transactions, interagency agreements,
memoranda of understanding, or other
Federal agreements, or activities directly
conducted by the Federal Government;
or
(b) Activities authorized in
accordance with the public health and
medical response of the Authority
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
78975
Having Jurisdiction to prescribe,
administer, deliver, distribute or
dispense the Covered Countermeasures
following a declaration of an emergency.
i. The Authority Having Jurisdiction
means the public agency or its delegate
that has legal responsibility and
authority for responding to an incident,
based on political or geographical (e.g.,
city, county, tribal, state, or Federal
boundary lines) or functional (e.g., law
enforcement, public health) range or
sphere of authority.
ii. A declaration of emergency means
any declaration by any authorized local,
regional, state, or Federal official of an
emergency specific to events that
indicate an immediate need to
administer and use the Covered
Countermeasures, with the exception of
a Federal Declaration in support of an
Emergency Use Authorization under
section 564 of the FD&C Act unless such
Declaration specifies otherwise;
I have also determined that for
governmental program planners only,
liability immunity is afforded only to
the extent such program planners obtain
Covered Countermeasures through
voluntary means, such as (1) donation;
(2) commercial sale; (3) deployment of
Covered Countermeasures from Federal
stockpiles; or (4) deployment of
donated, purchased, or otherwise
voluntarily obtained Covered
Countermeasures from state, local, or
private stockpiles.
VIII. Category of Disease, Health
Condition, or Threat
42 U.S.C. 247d–6d(b)(2)(A)
The category of disease, health
condition, or threat for which I
recommend the administration or use of
the Covered Countermeasures is
organophosphorus or carbamate
poisoning.
IX. Administration of Covered
Countermeasures
42 U.S.C. 247d–6d(a)(2)(B)
Administration of the Covered
Countermeasure means physical
provision of the countermeasures to
recipients, or activities and decisions
directly relating to public and private
delivery, distribution and dispensing of
the countermeasures to recipients,
management and operation of
countermeasure programs, or
management and operation of locations
for purpose of distributing and
dispensing countermeasures.
E:\FR\FM\23DEN1.SGM
23DEN1
78976
Federal Register / Vol. 87, No. 246 / Friday, December 23, 2022 / Notices
X. Population
42 U.S.C. 247d–6d(a)(4), 247d–
6d(b)(2)(C)
The populations of individuals
include any individual who uses or is
administered the Covered
Countermeasures in accordance with
this Declaration.
Liability immunity is afforded to
manufacturers and distributors without
regard to whether the countermeasure is
used by or administered to this
population; liability immunity is
afforded to program planners and
qualified persons when the
countermeasure is used by or
administered to this population or the
program planner or qualified person
reasonably could have believed the
recipient was in this population.
XIV. Countermeasures Injury
Compensation Program
XI. Geographic Area
42 U.S.C. 247d–6d(a)(4), 247d–
6d(b)(2)(D)
Liability immunity is afforded for the
administration or use of a Covered
Countermeasure without geographic
limitation.
Liability immunity is afforded to
manufacturers and distributors without
regard to whether the countermeasure is
used by or administered in these
geographic areas; liability immunity is
afforded to program planners and
qualified persons when the
countermeasure is used by or
administered in these geographic areas,
or the program planner or qualified
person reasonably could have believed
the recipient was in these geographic
areas.
TKELLEY on DSK125TN23PROD with NOTICE
XII. Effective Time Period
42 U.S.C. 247d–6d(b)(2)(B)
Liability immunity for Covered
Countermeasures obtained through
means of distribution other than in
accordance with the public health and
medical response of the Authority
Having Jurisdiction extends through
December 31, 2027.
Liability immunity for Covered
Countermeasures administered and
used in accordance with the public
health and medical response of the
Authority Having Jurisdiction begins
with a Declaration and lasts through (1)
the final day the emergency Declaration
is in effect or (2) December 31, 2027,
whichever occurs first.
XIII. Additional Time Period of
Coverage
42 U.S.C. 247d–6d(b)(3)(B) and (C)
I have determined that an additional
twelve (12) months of liability
protection is reasonable to allow for the
VerDate Sep<11>2014
20:36 Dec 22, 2022
manufacturer(s) to arrange for
disposition of the Covered
Countermeasure, including return of the
Covered Countermeasures to the
manufacturer, and for Covered Persons
to take other appropriate actions to limit
the administration or use of the Covered
Countermeasures.
Covered Countermeasures obtained
for the Strategic National Stockpile
(SNS) during the effective period of this
Declaration for Covered
Countermeasures obtained through
means of distribution other than in
accordance with the public health and
medical response of the Authority
Having Jurisdiction are covered through
the date of administration or use
pursuant to a distribution or release
from the SNS.
Jkt 259001
42 U.S.C. 247d–6e
The PREP Act authorizes the
Countermeasures Injury Compensation
Program (CICP) to provide benefits to
certain individuals or estates of
individuals who sustain a serious
physical covered injury as the direct
result of the administration or use of the
Covered Countermeasures and/or
benefits to certain survivors of
individuals who die as a direct result of
the administration or use of the Covered
Countermeasures. The causal
connection between the countermeasure
and the serious physical injury must be
supported by compelling, reliable, valid,
medical, and scientific evidence in
order for the individual to be considered
for compensation. The CICP is
administered by the Health Resources
and Services Administration, within the
Department of Health and Human
Services. Information about the CICP is
available at the toll-free number 1–855–
266–2427 or https://www.hrsa.gov
/cicp/.
XV. Amendments
42 U.S.C. 247d–6d(b)(4)
The April 11, 2017, Declaration Under
the Public Readiness and Emergency
Preparedness Act for Nerve Agents and
Insecticides Countermeasures was first
published on April 11, 2017. This is the
first amendment to that Declaration.
Further amendments to this
Declaration will be published in the
Federal Register.
Authority: 42 U.S.C. 247d–6d.
Xavier Becerra,
Secretary of Health and Human Services.
[FR Doc. 2022–28013 Filed 12–22–22; 8:45 am]
BILLING CODE 4150–37–P
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Notice of Amendment
ACTION:
Notice of amendment.
The Secretary is amending the
Declaration issued in the Federal
Register of August 1, 2016 as amended
and republished August 1, 2018,
pursuant to section 319F–3 of the Public
Health Service Act, to extend the
effective time period of the Republished
Declaration, as amended.
DATES: This Amendment of the August
1, 2018 Republished Declaration is
effective January 1, 2023.
FOR FURTHER INFORMATION CONTACT: L.
Paige Ezernack, Administration for
Strategic Preparedness and Response,
Department of Health and Human
Services, 200 Independence Avenue
SW, Washington, DC 20201; 202–260–
0365, paige.ezernack@hhs.gov.
SUPPLEMENTARY INFORMATION: The
Public Readiness and Emergency
Preparedness Act (PREP Act) authorizes
the Secretary of Health and Human
Services (the Secretary) to issue a
Declaration to provide liability
immunity to certain individuals and
entities (Covered Persons) against any
claim of loss caused by, arising out of,
relating to, or resulting from the
administration or use of medical
countermeasures (Covered
Countermeasures), except for claims
that meet the PREP Act’s definition of
willful misconduct. The Secretary may,
through publication in the Federal
Register, amend any portion of a
Declaration.
The PREP Act was enacted on
December 30, 2005, as Public Law 109–
148, Division C, Section 2. It amended
the Public Health Service (PHS) Act,
adding Section 319F–3, which
addresses liability immunity, and
Section 319F–4, which creates a
compensation program. These sections
are codified in the U.S. Code as 42
U.S.C. 247d–6d and 42 U.S.C. 247d–6e,
respectively. Section 319F–3 of the PHS
Act has been amended by the Pandemic
and All-Hazards Preparedness
Reauthorization Act (PAHPRA), Public
Law 113–5, enacted on March 13, 2013,
and the Coronavirus Aid, Relief, and
Economic Security (CARES) Act, Public
Law 116–136, enacted on March 27,
2020, to expand Covered
Countermeasures under the PREP Act.
The Secretary is now amending the
Republished Declaration to extend the
time period for which liability
immunity is in effect for all of the
SUMMARY:
E:\FR\FM\23DEN1.SGM
23DEN1
Agencies
[Federal Register Volume 87, Number 246 (Friday, December 23, 2022)]
[Notices]
[Pages 78974-78976]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-28013]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Notice of Amendment
ACTION: Notice of amendment.
-----------------------------------------------------------------------
SUMMARY: The Secretary is amending the Declaration issued in the
Federal Register of April 11, 2017, pursuant to section 319F-3 of the
Public Health Service Act to extend the effective time period of the
Declaration.
DATES: This amendment of the April 11, 2017 Declaration is effective
January 1, 2023.
FOR FURTHER INFORMATION CONTACT: L. Paige Ezernack, Administration for
Strategic Preparedness and Response, Department of Health and Human
Services, 200 Independence Avenue SW, Washington, DC 20201; 202-260-
0365, [email protected].
SUPPLEMENTARY INFORMATION: The Public Readiness and Emergency
Preparedness Act (PREP Act) authorizes the Secretary of Health and
Human Services (the Secretary) to issue a Declaration to provide
liability immunity to certain individuals and entities (Covered
Persons) against any claim of loss caused by, arising out of, relating
to, or resulting from the administration or use of medical
countermeasures (Covered Countermeasures), except for claims that meet
the PREP Act's definition of willful misconduct. The Secretary may,
through publication in the Federal Register, amend any portion of a
Declaration.
The PREP Act was enacted on December 30, 2005, as Public Law 109-
148, Division C, Section 2. It amended the Public Health Service (PHS)
Act, adding Section 319F-3, which addresses liability immunity, and
Section 319F-4, which creates a compensation program. These sections
are codified in the U.S. Code as 42 U.S.C. 247d-6d and 42 U.S.C. 247d-
6e, respectively. Section 319F-3 of the PHS Act has been amended by the
Pandemic and All-Hazards Preparedness Reauthorization Act (PAHPRA),
Public Law 113-5, enacted on March 13, 2013, and the Coronavirus Aid,
Relief, and Economic Security (CARES) Act, Public Law 116-136, enacted
on March 27, 2020, to expand Covered Countermeasures under the PREP
Act.
This Secretary is now amending the Declaration to extend the time
period for which liability immunity is in effect for all of the Covered
Countermeasures to December 31, 2027.
Renewal of PREP Act declaration for nerve agent and insecticide
threats is requested due to the continued national security threat
posed by these chemical threats. Nerve agent and insecticide threats
have the potential to cause significant morbidity and mortality in the
event of large-scale exposures. PREP Act coverage of countermeasures is
critical to the engagement with potential product sponsors due to the
limited commercial market of products in this threat space. Covered
countermeasures for nerve agents and insecticides will continue to be a
part of the preparedness posture for the United States, both in terms
of stockpiling current products and development next-generation
candidates. Extension of the PREP Act declaration for countermeasures
against nerve agents and insecticides is essential.
Unless otherwise noted, all statutory citations below are to the
U.S. Code.
[[Page 78975]]
Republished Declaration
Declaration, as Amended, for Public Readiness and Emergency
Preparedness Act Coverage for Nerve Agents and Certain Insecticides
(Organophosphorus and/or Carbamate) Countermeasures
This Declaration amends the April 11, 2017, Declaration under the
Public Readiness and Emergency Preparedness Act. To the extent any term
of the prior Declaration is inconsistent with any provision of this
Republished Declaration, the terms of this Republished Declaration are
controlling.
I. Determination of Public Health Emergency or Credible Risk of Future
Public Health Emergency
42 U.S.C. 247d-6d(b)(1)
I have determined that there is a credible risk that the release of
nerve agents or organophosphorus insecticides and the resulting
organophosphorus poisoning or release of carbamate insecticides and the
resulting carbamate poisoning may, in the future, constitute a public
health emergency.
II. Factors Considered
42 U.S.C. 247d-6d(b)(6)
I have considered the desirability of encouraging the design,
development, clinical testing, or investigation, manufacture, labeling,
distribution, formulation, packaging, marketing, promotion, sale,
purchase, donation, dispensing, prescribing, administration, licensing,
and use of the Covered Countermeasures.
III. Recommended Activities
42 U.S.C. 247d-6d(b)(1)
I recommend, under the conditions stated in this Declaration, the
manufacture, testing, development, distribution, administration, or use
of the Covered Countermeasures.
IV. Liability Immunity
42 U.S.C. 247d-6d(a), 247d-6d(b)(1)
Liability immunity as prescribed in the Public Readiness and
Emergency Preparedness (PREP) Act and conditions stated in this
Declaration is in effect for the Recommended Activities described in
Section III.
V. Covered Persons
42 U.S.C. 247d-6d(i)(2), (3), (4), (6), (8)(A) and (B)
Covered Persons who are afforded liability immunity under this
Declaration are manufacturers, distributors, program planners,
``qualified persons,'' and their officials, agents, and employees, as
those terms are defined in the PREP Act, and the United States.
In addition, I have determined that the following additional
persons are qualified persons: (a) Any person authorized in accordance
with the public health and medical emergency response of the Authority
Having Jurisdiction, as described in section VII below, to prescribe,
administer, deliver, distribute or dispense the Covered
Countermeasures, and their officials, agents, employees, contractors
and volunteers, following a declaration of an emergency; (b) Any person
authorized to prescribe, administer, or dispense the Covered
Countermeasures or who is otherwise authorized to perform an activity
under an Emergency Use Authorization in accordance with section 564 of
the Federal Food, Drug, and Cosmetic (FD&C) Act, and; (c) Any person
authorized to prescribe, administer, or dispense Covered
Countermeasures in accordance with Section 564A of the FD&C Act.
VI. Covered Countermeasures
42 U.S.C. 247d-6b(c)(1)(B), 42 U.S.C. 247d-6d(i)(1) and (7)
Covered Countermeasures are any antidote; any other drug; all
components and constituent materials of these antidotes and other
drugs; all devices and their constituent components used in the
administration of these antidotes and other drugs; any diagnostic; or
any other device to identify, prevent, or treat organophosphorus or
carbamate poisoning or adverse events from such countermeasures.
Covered Countermeasures must be ``qualified pandemic or epidemic
products,'' or ``security countermeasures,'' or drugs, biological
products, or devices authorized for investigational or emergency use,
as those terms are defined in the PREP Act, the FD&C Act, and the
Public Health Service Act.
VII. Limitations on Distribution
42 U.S.C. 247d-6d(a)(5) and (b)(2)(E)
I have determined that liability immunity is afforded to Covered
Persons only for Recommended Activities involving Covered
Countermeasures that are related to:
(a) Present or future Federal contracts, cooperative agreements,
grants, other transactions, interagency agreements, memoranda of
understanding, or other Federal agreements, or activities directly
conducted by the Federal Government;
or
(b) Activities authorized in accordance with the public health and
medical response of the Authority Having Jurisdiction to prescribe,
administer, deliver, distribute or dispense the Covered Countermeasures
following a declaration of an emergency.
i. The Authority Having Jurisdiction means the public agency or its
delegate that has legal responsibility and authority for responding to
an incident, based on political or geographical (e.g., city, county,
tribal, state, or Federal boundary lines) or functional (e.g., law
enforcement, public health) range or sphere of authority.
ii. A declaration of emergency means any declaration by any
authorized local, regional, state, or Federal official of an emergency
specific to events that indicate an immediate need to administer and
use the Covered Countermeasures, with the exception of a Federal
Declaration in support of an Emergency Use Authorization under section
564 of the FD&C Act unless such Declaration specifies otherwise;
I have also determined that for governmental program planners only,
liability immunity is afforded only to the extent such program planners
obtain Covered Countermeasures through voluntary means, such as (1)
donation; (2) commercial sale; (3) deployment of Covered
Countermeasures from Federal stockpiles; or (4) deployment of donated,
purchased, or otherwise voluntarily obtained Covered Countermeasures
from state, local, or private stockpiles.
VIII. Category of Disease, Health Condition, or Threat
42 U.S.C. 247d-6d(b)(2)(A)
The category of disease, health condition, or threat for which I
recommend the administration or use of the Covered Countermeasures is
organophosphorus or carbamate poisoning.
IX. Administration of Covered Countermeasures
42 U.S.C. 247d-6d(a)(2)(B)
Administration of the Covered Countermeasure means physical
provision of the countermeasures to recipients, or activities and
decisions directly relating to public and private delivery,
distribution and dispensing of the countermeasures to recipients,
management and operation of countermeasure programs, or management and
operation of locations for purpose of distributing and dispensing
countermeasures.
[[Page 78976]]
X. Population
42 U.S.C. 247d-6d(a)(4), 247d-6d(b)(2)(C)
The populations of individuals include any individual who uses or
is administered the Covered Countermeasures in accordance with this
Declaration.
Liability immunity is afforded to manufacturers and distributors
without regard to whether the countermeasure is used by or administered
to this population; liability immunity is afforded to program planners
and qualified persons when the countermeasure is used by or
administered to this population or the program planner or qualified
person reasonably could have believed the recipient was in this
population.
XI. Geographic Area
42 U.S.C. 247d-6d(a)(4), 247d-6d(b)(2)(D)
Liability immunity is afforded for the administration or use of a
Covered Countermeasure without geographic limitation.
Liability immunity is afforded to manufacturers and distributors
without regard to whether the countermeasure is used by or administered
in these geographic areas; liability immunity is afforded to program
planners and qualified persons when the countermeasure is used by or
administered in these geographic areas, or the program planner or
qualified person reasonably could have believed the recipient was in
these geographic areas.
XII. Effective Time Period
42 U.S.C. 247d-6d(b)(2)(B)
Liability immunity for Covered Countermeasures obtained through
means of distribution other than in accordance with the public health
and medical response of the Authority Having Jurisdiction extends
through December 31, 2027.
Liability immunity for Covered Countermeasures administered and
used in accordance with the public health and medical response of the
Authority Having Jurisdiction begins with a Declaration and lasts
through (1) the final day the emergency Declaration is in effect or (2)
December 31, 2027, whichever occurs first.
XIII. Additional Time Period of Coverage
42 U.S.C. 247d-6d(b)(3)(B) and (C)
I have determined that an additional twelve (12) months of
liability protection is reasonable to allow for the manufacturer(s) to
arrange for disposition of the Covered Countermeasure, including return
of the Covered Countermeasures to the manufacturer, and for Covered
Persons to take other appropriate actions to limit the administration
or use of the Covered Countermeasures.
Covered Countermeasures obtained for the Strategic National
Stockpile (SNS) during the effective period of this Declaration for
Covered Countermeasures obtained through means of distribution other
than in accordance with the public health and medical response of the
Authority Having Jurisdiction are covered through the date of
administration or use pursuant to a distribution or release from the
SNS.
XIV. Countermeasures Injury Compensation Program
42 U.S.C. 247d-6e
The PREP Act authorizes the Countermeasures Injury Compensation
Program (CICP) to provide benefits to certain individuals or estates of
individuals who sustain a serious physical covered injury as the direct
result of the administration or use of the Covered Countermeasures and/
or benefits to certain survivors of individuals who die as a direct
result of the administration or use of the Covered Countermeasures. The
causal connection between the countermeasure and the serious physical
injury must be supported by compelling, reliable, valid, medical, and
scientific evidence in order for the individual to be considered for
compensation. The CICP is administered by the Health Resources and
Services Administration, within the Department of Health and Human
Services. Information about the CICP is available at the toll-free
number 1-855-266-2427 or https://www.hrsa.gov/cicp/ /cicp/.
XV. Amendments
42 U.S.C. 247d-6d(b)(4)
The April 11, 2017, Declaration Under the Public Readiness and
Emergency Preparedness Act for Nerve Agents and Insecticides
Countermeasures was first published on April 11, 2017. This is the
first amendment to that Declaration.
Further amendments to this Declaration will be published in the
Federal Register.
Authority: 42 U.S.C. 247d-6d.
Xavier Becerra,
Secretary of Health and Human Services.
[FR Doc. 2022-28013 Filed 12-22-22; 8:45 am]
BILLING CODE 4150-37-P